You are here

Continuous Production of Organic Peroxyacid Antimicrobial Agents for Wound Care Using a Selective Plasma Oxidation Reactor

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43GM121092-01
Agency Tracking Number: R43GM121092
Amount: $224,983.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: 300
Solicitation Number: PA15-269
Solicitation Year: 2016
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-08-01
Award End Date (Contract End Date): 2018-01-31
Small Business Information
Fort Collins, CO 80523-0001
United States
DUNS: 828710215
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (970) 492-4418
Business Contact
Phone: (970) 492-4418
Research Institution

The prevalence of healthcare associated infections is a critical issue in the medical
community resulting in compromised patient healthcare and billions of dollars in corrective costs
Chronic non healing wounds affect approximately million people in the US each year with
an estimated annual cost of $ $ billion As such new methods are needed for producing
antimicrobial agents to treat microbes resistant to existing anti microbial agents in healthcare
settings In this Phase I SBIR proposal Symbios Technologies plasma technology will be applied
toward the production of anti infective solutions In collaboration with CHD Bioscience Symbios
will develop and optimize a Selective Plasma Oxidation Reactor SPOR for the alternate
production of CHD s flagship product VERIOXTM VERIOX is a proprietary blend of peroxyacid
compounds that demonstrates antimicrobial effects against a wide range of microbial
contaminants and is greatly promising as a commercial anti infective healthcare product
However the current VERIOX batch manufacturing process is cost safety and efficiency
limited since it reacts hydrogen peroxide with high concentrations of pyruvic acid at C
Due to high HOOH levels and low temperatures the production of VERIOX is currently cost
prohibitive and CHD has a difficult time identifying contract manufacturing organizations To
overcome such issues the Symbios SPOR represents a critical advancement to allow for
production of commercially relevant volumes of VERIOX in a safe continuous and low cost
fashion Use of the SPOR does not require external addition of HOOH due to plasma production
of oxidant species additionally the SPOR can be employed in a continuous flow configuration to
prevent the safety concerns associated with batch production Preliminary evidence suggests that
the Symbios platform is able to convert pyruvic acid to peroxyacid despite the presence of
iron containing surfaces that compromise peroxyacid stability Thus this Phase I proposal will
include a upgrading the reactor to eliminate iron surfaces followed by b optimization of the
system for peroxyacid production and analysis of the SPOR produced solutions compared to
VERIOX c preliminary disinfection efficacy studies and d economic modeling to inform
commercial scaling of the SPOR Overall use of the Symbios SPOR platform as an alternate
manufacturing platform will enable mass production of VERIOX in a safer and more cost effective
manner which will enable the commercial readiness of VERIOX in the healthcare space Phase
I work will set up nicely for Phase II where a more in depth compositional analysis will be
performed along with additional efficacy studies employing animal wound healing models Because there is a great unmet need for new anti infective products and scalable methods of
manufacture Symbios Technologies Inc is working in collaboration with its partner CHD
Bioscience Inc to develop a Selective Plasma Oxidation Reactor SPOR that can replace the
current manufacturing platform for CHD s antimicrobial and wound healing product VERIOX The
current VERIOX production method is severely limited by cost and safety issues where the
Symbios SPOR technology will enable production of commercially relevant volumes of VERIOX
in a safe continuous and low cost fashion as supported by preliminary evidence The VERIOX
product a proprietary blend of peroxyacid compounds shows great efficacy against a wide range
of microbial contaminants and is greatly promising as an anti infective healthcare product thus
the ability to enable commercial readiness of VERIOX will represent a marked improvement in
the healthcare space

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government